Skip to main content
Premium Trial:

Request an Annual Quote

Stemina Biomarker Discovery Raises $1M in Angel Funds

NEW YORK (GenomeWeb News) – Stemina Biomarker Discovery said this week that it has raised $1 million in angel investments to further develop its product for assessing drug toxicity in the developing human embryo.

Angel groups DaneVest Tech Fund Advisors, Phenomenelle Angels, and Wisconsin Investment Partners all contributed to the financing.

Stemina said that it plans to raise a total of $3 million in the financing round. In addition, the company said that it was recently awarded a $150,000 grant from the National Science Foundation.

Stemina, based in Madison, Wisc., will use the funds to broaden commercialization of its devTOX screen, expand the company's scientific and business development teams, finance additional equipment purchases, and cover operating expenses.

DevTox is a human embryonic stem cell- and metabolomics-based screen for assessing the toxicity of drugs on the developing human embryo. The company uses mass spectrometry to analyze small molecules secreted by hES cells, and differentiated cells such as heart and neural cells made from hES cells, in response to drugs, injury, or disease.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.